Depression treatment for Fort Lauderdale — measurement-based, 40 minutes away.

RECO Health's Delray Beach campus is 26 miles — about 40 minutes — north of Fort Lauderdale on I-95, close enough to commute to PHP without relocating from Las Olas, Victoria Park, or Coral Ridge. Depression care is delivered by in-house psychiatry to the STAR*D framework, tracked with PHQ-9 at every visit, and escalated to rTMS, IV ketamine, or Spravato when two adequate antidepressant trials have not produced remission. Every plan is anchored to measurement-based care rather than clinical impression.

For clients living in Las Olas, Victoria Park, Coral Ridge, Rio Vista, or Wilton Manors, RECO Health’s Delray Beach campus sits 26 miles north on I-95 — about 40 minutes in typical traffic. That distance is deliberate: close enough to commute to partial hospitalization without relocating a household, far enough that the clinical environment is genuinely separated from the neighborhoods, colleagues, and routines tied to a depressive episode. Our depression treatment program covers major depressive disorder, persistent depressive disorder, and treatment-resistant depression at PHP and IOP levels of care — with in-house psychiatry, protocol-driven psychotherapy, and access to interventional options including rTMS and IV ketamine when clinically indicated.

Diagnostic formulation and severity staging

The initial evaluation is diagnostic before it is therapeutic. A RECO Health psychiatrist distinguishes major depressive disorder from persistent depressive disorder, bipolar II depression, adjustment disorder with depressed mood, and depressive syndromes secondary to hypothyroidism, B12 deficiency, or ongoing substance use — because the treatment plans diverge sharply. Missed bipolarity treated with SSRI monotherapy can precipitate a hypomanic switch; missed hypothyroidism responds to levothyroxine, not sertraline.

Severity is anchored numerically. The PHQ-9 stages depressive severity from minimal to severe; the Columbia-Suicide Severity Rating Scale (C-SSRS) captures the presence, intensity, and behavior of suicidal ideation; the GAD-7 screens the anxiety comorbidity that co-travels with roughly two-thirds of depressive presentations. Baseline labs — TSH with reflex free T4, B12, folate, vitamin D, and a comprehensive metabolic panel — screen for medical contributors before any psychotropic is written.

Level of care follows severity. PHP is indicated for severe presentations, acute suicidality without imminent plan, or significant functional collapse; IOP fits moderate depression with preserved daily functioning. That decision is made against ASAM Criteria dimensions when a co-occurring substance use disorder is present, and against MCG behavioral health criteria for pure mood disorder presentations.

Pharmacology sequenced by evidence, not habit

First-line pharmacotherapy for major depressive disorder follows the STAR*D framework: an SSRI (sertraline, escitalopram) or SNRI (venlafaxine XR, duloxetine), titrated to therapeutic dose over two to four weeks and held there for a four-to-six-week response window before the plan is revisited. Undertreatment — cycling patients through subtherapeutic doses — is the most common reason “the last three antidepressants didn’t work.”

Partial responders are augmented rather than switched. Aripiprazole (2–5 mg) and brexpiprazole carry the strongest FDA labeling for adjunctive use; lithium augmentation retains a specific role in suicidality reduction; bupropion adds noradrenergic-dopaminergic coverage for anhedonia and fatigue. For clients whose depression is layered with insomnia and agitation, mirtazapine at 15–30 mg addresses both. Quetiapine XR and olanzapine-fluoxetine combination remain options when depression carries prominent anxiety or a bipolar spectrum concern, weighed against metabolic risk.

Treatment-resistant depression — defined as failure of two adequate antidepressant trials at therapeutic dose and duration — is not treated by cycling into a fifth SSRI. It triggers staging for rTMS, esketamine, or IV ketamine, with the choice driven by insurance eligibility, suicidality timeline, and medical comorbidities. Every medication decision is documented alongside PHQ-9 trajectory rather than clinical impression.

Evidence-based psychotherapy for depression

Psychotherapy at RECO Health is delivered to protocol. Cognitive Behavioral Therapy for depression targets the cognitive distortions — catastrophizing, all-or-nothing thinking, personalization — that maintain depressed mood, paired with behavioral experiments that test those distortions against reality. Behavioral Activation, often deployed first when anhedonia is the presenting problem, systematically restores rewarding and mastery activities before cognitive restructuring begins.

Interpersonal Therapy is used when the depressive episode is anchored to grief, role transition, interpersonal role dispute, or interpersonal deficits — situations where relational context drives the mood disorder rather than sitting incidental to it. For clients whose depression is comorbid with post-traumatic stress or a documented trauma history, Cognitive Processing Therapy or EMDR is layered in rather than deferred, because untreated trauma tends to hold the depression in place.

Group programming supplements individual work. DBT skills groups (mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness) are indicated when depression sits alongside emotional dysregulation or self-harm behavior. ACT groups address depression driven by experiential avoidance and rigid values-behavior gaps. Motivational Interviewing runs underneath every modality when ambivalence about treatment engagement is the barrier.

The escalation pathway when medication and therapy aren’t enough

Roughly a third of clients with major depressive disorder will not achieve remission after two adequate antidepressant trials. RECO Health’s escalation pathway is defined in advance rather than negotiated after months of drift. The three interventional options — repetitive transcranial magnetic stimulation, IV ketamine, and esketamine — each occupy a specific clinical slot.

rTMS uses the FDA-cleared 10 Hz protocol over the left dorsolateral prefrontal cortex — 3000 pulses per session at 120% of resting motor threshold, delivered five days per week for approximately six weeks (36 sessions plus a taper). It is typically the first interventional step for insurance-eligible TRD when the client can commit to daily sessions and is not in acute suicidal crisis. There is no anesthesia and no cognitive side-effect profile of the kind associated with ECT.

IV ketamine (0.5 mg/kg over 40 minutes, six-infusion induction across two to three weeks) is chosen when the response timeline matters — acute suicidal ideation, imminent job or custody loss, functional collapse that will not tolerate a six-week rTMS course. Esketamine (Spravato) is the REMS-monitored intranasal alternative when insurance coverage or a client’s preference for supervised in-clinic delivery makes it the better fit. All three are prescribed and monitored by RECO’s in-house psychiatrists, not outsourced.

What to expect on the first visit from Fort Lauderdale

The first appointment is scheduled as an in-person psychiatric intake at the Delray Beach campus. Clients driving up from Fort Lauderdale typically allow 40 minutes on I-95 north to Atlantic Avenue. The intake block runs 90 minutes: a diagnostic interview against DSM-5-TR criteria, PHQ-9 and GAD-7 administration, C-SSRS suicide-risk screen, and — when a substance use component is present — CIWA (alcohol) or COWS (opioid) scoring for withdrawal risk.

By the end of the first visit, a preliminary formulation is documented, a level-of-care recommendation (PHP or IOP) is made, and — if pharmacotherapy is indicated — a starting regimen is written. Labs are ordered the same day; a follow-up psychiatric visit is scheduled within one week, not one month. Group and individual therapy begin the following business day for clients who accept a treatment plan.

Insurance and admissions from Fort Lauderdale

RECO Health is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield plans commonly held by Broward County residents. Verification of benefits is completed by the admissions team before the intake appointment so that PHP or IOP authorization, session limits, and out-of-pocket costs are transparent up front. For clients whose plan requires prior authorization, RECO’s utilization review staff manage the clinical documentation directly with the payer.

For Fort Lauderdale clients whose commute or clinical presentation makes daily travel impractical, structured housing near the Delray Beach campus is available for the PHP phase, with a step-down to daily commute at IOP. Admissions can be reached seven days a week; most clients are seen for intake within 48 hours of first contact.

Serving residents of: Las Olas, Victoria Park, Coral Ridge, Rio Vista, Wilton Manors.